| Summary of Significant Segment Expenses |
The following table presents the significant segment expenses for the three months and six months ended June 30, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|
|
June 30, |
|
|
June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Clinical and development costs |
|
$ |
7,093 |
|
|
$ |
11,834 |
|
|
$ |
15,373 |
|
|
$ |
22,371 |
|
Preclinical costs |
|
|
524 |
|
|
|
618 |
|
|
|
459 |
|
|
|
1,856 |
|
Personnel and related costs |
|
|
3,455 |
|
|
|
3,582 |
|
|
|
6,630 |
|
|
|
11,145 |
|
Stock-based compensation expense |
|
|
1,278 |
|
|
|
840 |
|
|
|
2,479 |
|
|
|
3,845 |
|
Other research costs |
|
|
788 |
|
|
|
1,148 |
|
|
|
1,803 |
|
|
|
2,693 |
|
Total research and development expenses |
|
|
13,138 |
|
|
|
18,022 |
|
|
|
26,744 |
|
|
|
41,910 |
|
General and administrative expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Personnel and related costs |
|
|
1,855 |
|
|
|
1,876 |
|
|
|
3,696 |
|
|
|
4,701 |
|
Stock-based compensation expense |
|
|
1,405 |
|
|
|
1,296 |
|
|
|
2,713 |
|
|
|
3,507 |
|
Other general and administrative costs |
|
|
1,873 |
|
|
|
2,279 |
|
|
|
4,084 |
|
|
|
5,175 |
|
Total general and administrative expenses |
|
|
5,133 |
|
|
|
5,451 |
|
|
|
10,493 |
|
|
|
13,383 |
|
Lease termination (gain) and impairment charge: |
|
|
|
|
|
|
|
|
|
|
|
|
Lease termination (gain) and impairment charge |
|
|
(238 |
) |
|
|
3,175 |
|
|
|
(238 |
) |
|
|
3,175 |
|
Total lease termination (gain) and impairment charge |
|
|
(238 |
) |
|
|
3,175 |
|
|
|
(238 |
) |
|
|
3,175 |
|
Loss from operations |
|
|
(18,033 |
) |
|
|
(26,648 |
) |
|
|
(36,999 |
) |
|
|
(58,468 |
) |
Interest income |
|
|
1,508 |
|
|
|
1,106 |
|
|
|
2,690 |
|
|
|
2,589 |
|
Interest expense |
|
|
(285 |
) |
|
|
(405 |
) |
|
|
(616 |
) |
|
|
(811 |
) |
Other expense, net |
|
|
(257 |
) |
|
|
(2 |
) |
|
|
(69 |
) |
|
|
(13 |
) |
Loss on debt extinguishment |
|
|
(904 |
) |
|
|
— |
|
|
|
(904 |
) |
|
|
— |
|
Net loss |
|
$ |
(17,971 |
) |
|
$ |
(25,949 |
) |
|
$ |
(35,898 |
) |
|
$ |
(56,703 |
) |
|